Protalix BioTherapeutics, Inc. (PLX) Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount

Protalix BioTherapeutics, Inc. Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount

Protalix BioTherapeutics, Inc. (PLX) reported Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount of -$953.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-18.

Financial Statements › Expense Statement › Income Tax

us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance · last filed 2026-03-18

• Protalix BioTherapeutics, Inc. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for the quarter ending 2023-09-30 was $3.10M.
• Protalix BioTherapeutics, Inc. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for the quarter ending 2023-06-30 was -$3.10M.
• Protalix BioTherapeutics, Inc. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for fiscal 2024 was -$953.00K.
• Protalix BioTherapeutics, Inc. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for fiscal 2023 was -$6.93M.
• Protalix BioTherapeutics, Inc. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for fiscal 2022 was -$2.97M, a 151.28% decline from fiscal 2021.
• Protalix BioTherapeutics, Inc. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for fiscal 2021 was $5.79M.